Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VerastemVSTM +2.39%17 Operating Cash Flow per Share is $-1.82 as of Jun. 2026. GuruFocus rates VSTM with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,130 Biotechnology companies, Verastem ranks better than 53.81% on this metric.
Verastem's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.44.
Verastem's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.82.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 5.80% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 19.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Verastem's Operating Cash Flow per Share or its related term are showing as below:
VSTM'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -45.6 Med: 6.35 Max: 47.3
Current: 20.5
During the past 13 years, Verastem's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.30% per year. The lowest was -45.60% per year. And the median was 6.35% per year.
VSTM's 3-Year OCF Growth Rate is ranked better than 53.81% of 1130
companies
in the Biotechnology industry
Industry Median: 16.85
vs VSTM: 20.50
Verastem Operating Cash Flow per Share Related Terms
Verastem Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Verastem's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VSTM vs PRME, MDXG, SGMT: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Verastem's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verastem Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verastem's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Verastem's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-1.82 mean?
Verastem (VSTM) has a Operating Cash Flow per Share of $-1.82 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Verastem and its competitors. According to the industry distribution chart, Verastem ranks #522 out of 1130 companies in the Biotechnology industry, placing it in the top 46.2%.
Is Verastem's Operating Cash Flow per Share too high?
Verastem's current Operating Cash Flow per Share is $-1.82. Based on the distribution chart, Verastem ranks #522 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Verastem has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Verastem's Operating Cash Flow per Share compare to PRME and MDXG?
According to the Biotechnology industry distribution chart, Verastem ranks #522 out of 1130 companies for Operating Cash Flow per Share. This puts Verastem in the upper half of its industry. The industry median Operating Cash Flow per Share is 16.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Verastem and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verastem's current Operating Cash Flow per Share is $-1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verastem stock overvalued right now?
Verastem (VSTM) has a current Operating Cash Flow per Share of $-1.82. The current Operating Cash Flow per Share is $-1.82. Verastem's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Verastem (VSTM), the current Operating Cash Flow per Share is $-1.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
17GF Score
Get the complete analysis for VSTM
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VSTM has been successfully added to your 
